BR112019004764A2 - inibidores bicíclicos fundidos da interação menina-mll - Google Patents

inibidores bicíclicos fundidos da interação menina-mll

Info

Publication number
BR112019004764A2
BR112019004764A2 BR112019004764A BR112019004764A BR112019004764A2 BR 112019004764 A2 BR112019004764 A2 BR 112019004764A2 BR 112019004764 A BR112019004764 A BR 112019004764A BR 112019004764 A BR112019004764 A BR 112019004764A BR 112019004764 A2 BR112019004764 A2 BR 112019004764A2
Authority
BR
Brazil
Prior art keywords
girl
fused bicyclic
mll interaction
inhibitors
bicyclic inhibitors
Prior art date
Application number
BR112019004764A
Other languages
English (en)
Inventor
Nathaniel Patrick Aaron
Herkert Barbara
Jason Krosky Daniel
Alexis Georges Querolle Olivier
René Angibaud Patrick
Pande Vineet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112019004764A2 publication Critical patent/BR112019004764A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a agentes farmacêuticos úteis para terapia e/ou profilaxia em um mamífero, e em particular, com compostos bicíclicos fundidos, composição farmacêutica compreendendo tais compostos e seu uso como inibidores da interação proteína/proteína menina/mll, úteis para tratamento de doenças tais como câncer, síndrome mielodisplásica (mds) e diabetes.
BR112019004764A 2016-09-14 2017-09-13 inibidores bicíclicos fundidos da interação menina-mll BR112019004764A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662394291P 2016-09-14 2016-09-14
EP16192424 2016-10-05
EP17180228 2017-07-07
PCT/EP2017/073001 WO2018050684A1 (en) 2016-09-14 2017-09-13 Fused bicyclic inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
BR112019004764A2 true BR112019004764A2 (pt) 2019-05-28

Family

ID=59901513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004764A BR112019004764A2 (pt) 2016-09-14 2017-09-13 inibidores bicíclicos fundidos da interação menina-mll

Country Status (14)

Country Link
US (2) US10611778B2 (pt)
EP (1) EP3512858B1 (pt)
JP (1) JP7033141B2 (pt)
KR (1) KR102493364B1 (pt)
CN (1) CN109715634B (pt)
AU (1) AU2017326485B2 (pt)
BR (1) BR112019004764A2 (pt)
CA (1) CA3033020A1 (pt)
ES (1) ES2966316T3 (pt)
IL (1) IL265231B (pt)
MA (1) MA46228A (pt)
MX (1) MX2019002959A (pt)
TW (1) TWI753016B (pt)
WO (1) WO2018050684A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2017161002A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
SI3429591T1 (sl) 2016-03-16 2023-07-31 Kura Oncology, Inc. Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
EP3512858B1 (en) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Fused bicyclic inhibitors of menin-mll interaction
US10745409B2 (en) 2016-12-15 2020-08-18 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液***恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN112105621B (zh) * 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
CN112771055B (zh) * 2018-08-08 2023-10-20 住友制药株式会社 光学活性桥接哌啶衍生物
BR112021002090A8 (pt) * 2018-08-27 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Derivado azabicíclico opticamente ativo
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
BR112023021040A2 (pt) 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
JP2024518434A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
JP2024521879A (ja) 2021-06-01 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体
CA3218340A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
KR20240021808A (ko) 2021-06-17 2024-02-19 얀센 파마슈티카 엔브이 암과 같은 질환의 치료를 위한 (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드 베실레이트 염
TW202317560A (zh) * 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
IL163613A0 (en) 2002-02-19 2005-12-18 Cv Therapeutics Inc Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
WO2004056800A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
US20080102068A1 (en) * 2005-01-19 2008-05-01 Coleman Paul J Mitotic Kinesin Inhibitors
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) * 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
CA2894130A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
PT2935222T (pt) 2012-12-21 2018-12-10 Epizyme Inc Inibidores de prmt5 e seus usos
CA2904612A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2015191701A1 (en) 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
USRE49687E1 (en) * 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10526341B2 (en) 2014-11-19 2020-01-07 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
CU20170105A7 (es) 2015-02-24 2017-10-05 Pfizer Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
US20190010167A1 (en) 2015-12-22 2019-01-10 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
SI3429591T1 (sl) 2016-03-16 2023-07-31 Kura Oncology, Inc. Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
WO2017161002A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
BR112018072570A2 (pt) 2016-05-02 2019-02-19 Univ Michigan Regents piperidinas como inibidores de menina
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
KR102436430B1 (ko) 2016-06-10 2022-08-24 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
TWI738864B (zh) 2016-09-14 2021-09-11 比利時商健生藥品公司 Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑
EP3512858B1 (en) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Fused bicyclic inhibitors of menin-mll interaction
CA3036987A1 (en) 2016-09-16 2018-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液***恶性肿瘤和尤因肉瘤的方法

Also Published As

Publication number Publication date
MX2019002959A (es) 2019-07-04
US10611778B2 (en) 2020-04-07
MA46228A (fr) 2019-07-24
US20190218230A1 (en) 2019-07-18
EP3512858C0 (en) 2023-11-08
WO2018050684A1 (en) 2018-03-22
US10975100B2 (en) 2021-04-13
KR20190046888A (ko) 2019-05-07
TWI753016B (zh) 2022-01-21
JP2019530745A (ja) 2019-10-24
TW201823249A (zh) 2018-07-01
CN109715634B (zh) 2022-09-27
ES2966316T3 (es) 2024-04-19
IL265231B (en) 2021-06-30
EP3512858A1 (en) 2019-07-24
JP7033141B2 (ja) 2022-03-09
CA3033020A1 (en) 2018-03-22
AU2017326485B2 (en) 2021-04-22
KR102493364B1 (ko) 2023-01-27
CN109715634A (zh) 2019-05-03
US20200172556A1 (en) 2020-06-04
IL265231A (en) 2019-05-30
EP3512858B1 (en) 2023-11-08
AU2017326485A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
BR112019004764A2 (pt) inibidores bicíclicos fundidos da interação menina-mll
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
BR112018012707A2 (pt) inibidores da interação de menin-mll
BR112019005030A2 (pt) inibidores da interação de menina-llm
DOP2018000026A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
BR112018075260A2 (pt) inibidores da interação de menina-llm
BR112015022942A2 (pt) heterociclos tricíclicos como inibidores da proteína bet
AR094867A1 (es) Conjugados de anticuerpos y sus usos
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112016013861A2 (pt) conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112016014830A2 (pt) Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
BR112016004073A8 (pt) Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3
CR20190394A (es) Compuestos de inhibidores de autotaxina
CY1119667T1 (el) Υποκατεστημενες ιμιδαζοπυριδαζινες
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
BR112015029367A8 (pt) combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]